Blueprint Medicines CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Blueprint Medicines Corporation has scheduled its 2025 Annual Meeting for June 18, 2025, and is providing proxy materials to stockholders for voting on key proposals.
Blueprint Medicines reports significant progress in 2024, driven by AYVAKIT sales and pipeline advancements, setting sights on \$2 billion in revenue by 2030.
Blueprint Medicines highlights a successful 2023 with regulatory approvals and commercial launches of AYVAKIT/AYVAKYT, setting the stage for continued growth and pipeline advancement in 2024.